Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Andavarapu v. iBio Inc. et al
Case Number:
1:14-cv-01343
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
April 21, 2016
IBio Settles Investor Suit Over Ebola Drug Plans For $1.87M
Pharmaceutical company iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1.87 million and attorneys' fees for allegedly fabricating a joint venture to manufacture an Ebola treatment in an effort to pump up the company's value at a time when the disease was ravaging Africa.
-
October 27, 2014
Biotech Co. Misled Investors About Role In Ebola Drug: Suit
A shareholder of plant-based pharmaceutical manufacturer iBio Inc. hit the company with a putative class action in Delaware federal court on Friday, alleging that iBio inflated its stock price by misleading investors about its role in manufacturing a new Ebola treatment.